SB
AEGR

Suntrust Banks’s Aegerion Pharmaceuticals AEGR Stock Holding History

Suntrust Banks’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,468
Closed -$211K – 1915
2013
Q3 		$211K Buy
+2,468
New +$209K ﹤0.01% 1658

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Suntrust Banks's AEGR Position: Q4 2013 in Review

Suntrust Banks sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2013, closing a stake of 2,468 shares — an estimated $211K sold.

Suntrust Banks first reported a position in AEGR in Q3 2013 and held it in 1 quarter. The position peaked at $211K in Q3 2013. 150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

  • Suntrust Banks reported no remaining Aegerion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Suntrust Banks sold 2,468 Aegerion Pharmaceuticals shares in Q4 2013, an estimated $211K.
  • Suntrust Banks first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Suntrust Banks's Aegerion Pharmaceuticals position peaked at $211K in Q3 2013.
  • 150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Suntrust Banks's 13F filing for Q4 2013, filed 12 Feb 2014.